Comparing Cyanotech (CYAN) & Pharmacyte Biotech (PMCB)

Cyanotech ( NASDAQ:CYAN ) and Pharmacyte Biotech ( OTCMKTS:PMCB ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Risk and Volatility

Cyanotech has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Pharmacyte Biotech has a beta of 2.94, suggesting that its share price is 194% more volatile than the S&P 500.

Institutional and Insider Ownership

13.6% of Cyanotech shares are held by institutional investors. Comparatively, 0.1% of Pharmacyte Biotech shares are held by institutional investors. 24.5% of Cyanotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Cyanotech and Pharmacyte Biotech, as provided by Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyanotech 0 0 0 0 N/A Pharmacyte Biotech 0 0 0 0 N/A Valuation and Earnings

This table compares Cyanotech and Pharmacyte Biotech’s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cyanotech $34.12 million 0.54 $1.02 million N/A N/A Pharmacyte Biotech N/A N/A -$6.82 million N/A N/A Cyanotech has higher revenue and earnings than Pharmacyte Biotech.


This table compares Cyanotech and Pharmacyte Biotech’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Cyanotech -7.53% -13.51% -7.90% Pharmacyte Biotech N/A -96.25% -84.93% Summary

Cyanotech beats Pharmacyte Biotech on 6 of the 8 factors compared between the two stocks.

Cyanotech Company Profile Cyanotech logo Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. The company’s products include Hawaiian BioAstin natural astaxanthin, a dietary antioxidant, which is used as a human nutraceutical and functional food ingredient to support and maintain the body’s natural inflammatory response, enhance skin, and support eye and joint health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. Cyanotech Corporation sells its products as packaged consumer products through distributors, retailers, and online channels, as well as directly to consumers; and in bulk quantities to manufacturers, formulators, and distributors. The company was founded in 1983 and is headquartered in Kailua-Kona, Hawaii.

Pharmacyte Biotech Company Profile

PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.

Receive News & Ratings for Cyanotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cyanotech and related companies with’s FREE daily email newsletter .

Tags:, ,

Add a Comment

Your email address will not be published.